Athenix Body Sculpting Institute Achieves Accreditation by AAAHC

December 23, 2020

Athenix Body Sculpting Institute, a leading aesthetic plastic surgery center on the West Coast, was granted a three-year accreditation by Accreditation Association for Ambulatory Health Care (AAAHC) to its Bellevue, Washington and Portland, Oregon facilities.

Athenix Body Sculpting Institute Fresno, CA, location, as well as its Southern California locations, has maintained accreditation by the Institute for Medical Quality (IMQ) at its California locations for the past 10 years.

“We are pleased to announce all five of our Athenix Body Sculpting centers have achieved accreditation by either AAAHC or IMQ,” says  Dr. Gavin Dry, Medical Director of Athenix. “This speaks directly to the extensive safety standards we have put in place for our patients, as well as our ongoing dedication to providing the absolute best patient care and results.”

AAAHC advocates for the provision of high-quality health care through the development and adoption of nationally recognized standards. The AAAHC Certificate of Accreditation demonstrates an organization’s commitment to providing safe, high-quality services to its patients—every day of the 1,095-day accreditation cycle. It is recognized by third party payers, medical professional associations, liability insurance companies, state and federal agencies, and the public.

Over the last decade, Athenix has served over 50,000 satisfied patients throughout the west coast, offering a full spectrum of aesthetic plastic surgery procedures including body contouring, breast augmentation and reduction, as well as the latest minimally-invasive cosmetic procedures. Accreditation further distinguishes Athenix Body Sculpting Institute by recognizing its strict adherence to the rigorous standards of care and safety set forth by the AAAHC.

In order to achieve AAAHC accreditation, Athenix agreed to extensive on-site reviews, ongoing self-evaluation, and a commitment to continuously improve its care and services. The on-site survey was conducted by AAAHC expert surveyors – physicians, nurses, and administrators who are actively involved in ambulatory care. Athenix now joins more than 6,100 ambulatory health care organizations across the United States to be currently accredited by AAAHC.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”